1
|
Homanics GE, Park JE, Bailey L, Schaeffer DJ, Schaeffer L, He J, Li S, Zhang T, Haber A, Spruce C, Greenwood A, Murai T, Schultz L, Mongeau L, Ha SK, Oluoch J, Stein B, Choi SH, Huhe H, Thathiah A, Strick PL, Carter GW, Silva AC, Sukoff Rizzo SJ. Early molecular events of autosomal-dominant Alzheimer's disease in marmosets with PSEN1 mutations. Alzheimers Dement 2024. [PMID: 38574388 DOI: 10.1002/alz.13806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 02/27/2024] [Accepted: 02/28/2024] [Indexed: 04/06/2024]
Abstract
INTRODUCTION Fundamental questions remain about the key mechanisms that initiate Alzheimer's disease (AD) and the factors that promote its progression. Here we report the successful generation of the first genetically engineered marmosets that carry knock-in (KI) point mutations in the presenilin 1 (PSEN1) gene that can be studied from birth throughout lifespan. METHODS CRISPR/Cas9 was used to generate marmosets with C410Y or A426P point mutations in PSEN1. Founders and their germline offspring are comprehensively studied longitudinally using non-invasive measures including behavior, biomarkers, neuroimaging, and multiomics signatures. RESULTS Prior to adulthood, increases in plasma amyloid beta were observed in PSEN1 mutation carriers relative to non-carriers. Analysis of brain revealed alterations in several enzyme-substrate interactions within the gamma secretase complex prior to adulthood. DISCUSSION Marmosets carrying KI point mutations in PSEN1 provide the opportunity to study the earliest primate-specific mechanisms that contribute to the molecular and cellular root causes of AD onset and progression. HIGHLIGHTS We report the successful generation of genetically engineered marmosets harboring knock-in point mutations in the PSEN1 gene. PSEN1 marmosets and their germline offspring recapitulate the early emergence of AD-related biomarkers. Studies as early in life as possible in PSEN1 marmosets will enable the identification of primate-specific mechanisms that drive disease progression.
Collapse
Affiliation(s)
- Gregg E Homanics
- Department of Anesthesiology & Perioperative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Jung Eun Park
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Lauren Bailey
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - David J Schaeffer
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Lauren Schaeffer
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Jie He
- Department of Statistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Shuoran Li
- Department of Statistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Tingting Zhang
- Department of Statistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Annat Haber
- The Jackson Laboratory, Bar Harbor, Maine, USA
| | | | | | - Takeshi Murai
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Laura Schultz
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Lauren Mongeau
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Seung-Kwon Ha
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Julia Oluoch
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Brianne Stein
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Sang Ho Choi
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Hasi Huhe
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Amantha Thathiah
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Peter L Strick
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | | - Afonso C Silva
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Stacey J Sukoff Rizzo
- Department of Neurobiology, University of Pittsburgh Brain Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
2
|
Murai T, Bailey L, Schultz L, Mongeau L, DeSana A, Silva AC, Roberts AC, Sukoff Rizzo SJ. Improving preclinical to clinical translation of cognitive function for aging-related disorders: the utility of comprehensive touchscreen testing batteries in common marmosets. Cogn Affect Behav Neurosci 2024; 24:325-348. [PMID: 38200282 DOI: 10.3758/s13415-023-01144-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/04/2023] [Indexed: 01/12/2024]
Abstract
Concerns about poor animal to human translation have come increasingly to the fore, in particular with regards to cognitive improvements in rodent models, which have failed to translate to meaningful clinical benefit in humans. This problem has been widely acknowledged, most recently in the field of Alzheimer's disease, although this issue pervades the spectrum of central nervous system (CNS) disorders, including neurodevelopmental, neuropsychiatric, and neurodegenerative diseases. Consequently, recent efforts have focused on improving preclinical to clinical translation by incorporating more clinically analogous outcome measures of cognition, such as touchscreen-based assays, which can be employed across species, and have great potential to minimize the translational gap. For aging-related research, it also is important to incorporate model systems that facilitate the study of the long prodromal phase in which cognitive decline begins to emerge and which is a major limitation of short-lived species, such as laboratory rodents. We posit that to improve translation of cognitive function and dysfunction, nonhuman primate models, which have conserved anatomical and functional organization of the primate brain, are necessary to move the field of translational research forward and to bridge the translational gaps. The present studies describe the establishment of a comprehensive battery of touchscreen-based tasks that capture a spectrum of domains sensitive to detecting aging-related cognitive decline, which will provide the greatest benefit through longitudinal evaluation throughout the prolonged lifespan of the marmoset.
Collapse
Affiliation(s)
- Takeshi Murai
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Lauren Bailey
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Laura Schultz
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Lauren Mongeau
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Andrew DeSana
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Afonso C Silva
- Department of Neurobiology, University of Pittsburgh School of Medicine, 514A Bridgeside Point 1, 100 Technology Drive, Pittsburgh, PA, 15219, USA
| | - Angela C Roberts
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Stacey J Sukoff Rizzo
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Department of Neurobiology, University of Pittsburgh School of Medicine, 514A Bridgeside Point 1, 100 Technology Drive, Pittsburgh, PA, 15219, USA.
| |
Collapse
|
3
|
Sasner M, Onos KD, Territo PR, Sukoff Rizzo SJ. Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research. Alzheimers Dement 2024. [PMID: 38400713 DOI: 10.1002/alz.13742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 01/19/2024] [Accepted: 01/22/2024] [Indexed: 02/25/2024]
Abstract
The fifth annual workshop on Principles and Techniques for Improving Preclinical Translation of Alzheimer's Disease Research was held in May 2023 at The Jackson Laboratory in Bar Harbor, Maine, USA. The workshop was established in 2018 to address training gaps in preclinical translational studies for Alzheimer's disease (AD). In addition to providing fundamental knowledge and hands-on skills essential for executing rigorous in vivo studies that are designed to facilitate translation, each year the workshop aims to provide insight on state-of-the-field technological advances and new resources including novel animal models, publicly available datasets, novel biomarkers, and new medical imaging tracers. This innovative and comprehensive workshop continues to deliver training for the greater AD research community in order to provide investigators and trainees with the knowledge and skillsets essential for enabling improved preclinical to clinical translation and accelerate the process of advancing safe and effective therapeutic interventions for AD. HIGHLIGHTS: Translational research is not typically available as a course of study at academic institutions, yet there are fundamental skillsets and knowledge required to enable successful translation from preclinical experiments to clinical efficacy. It is important that there are resources and opportunities available to researchers planning preclinical translational experiments. Here we present proceedings from the fifth annual NIA-sponsored workshop focused on enabling improved preclinical to clinical translation for Alzheimer's disease research that includes didactic lectures on state-of-the-field approaches and hands-on practicums for acquiring essential translational laboratory techniques.
Collapse
Affiliation(s)
| | | | - Paul R Territo
- Indiana University School of Medicine, Department of Medicine, Division of Clinical Pharmacology, Indianapolis, Indiana, USA
- Indiana University School of Medicine, Stark Neurosciences Research Institute, Indianapolis, Indiana, USA
| | - Stacey J Sukoff Rizzo
- University of Pittsburgh School of Medicine - Aging Institute, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
4
|
Roy TA, Bubier JA, Dickson PE, Wilcox TD, Ndukum J, Clark JW, Sukoff Rizzo SJ, Crabbe JC, Denegre JM, Svenson KL, Braun RE, Kumar V, Murray SA, White JK, Philip VM, Chesler EJ. Discovery and validation of genes driving drug-intake and related behavioral traits in mice. Genes Brain Behav 2024; 23:e12875. [PMID: 38164795 PMCID: PMC10780947 DOI: 10.1111/gbb.12875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 11/08/2023] [Accepted: 11/12/2023] [Indexed: 01/03/2024]
Abstract
Substance use disorders are heritable disorders characterized by compulsive drug use, the biological mechanisms for which remain largely unknown. Genetic correlations reveal that predisposing drug-naïve phenotypes, including anxiety, depression, novelty preference and sensation seeking, are predictive of drug-use phenotypes, thereby implicating shared genetic mechanisms. High-throughput behavioral screening in knockout (KO) mice allows efficient discovery of the function of genes. We used this strategy in two rounds of candidate prioritization in which we identified 33 drug-use candidate genes based upon predisposing drug-naïve phenotypes and ultimately validated the perturbation of 22 genes as causal drivers of substance intake. We selected 19/221 KO strains (8.5%) that had a difference from control on at least one drug-naïve predictive behavioral phenotype and determined that 15/19 (~80%) affected the consumption or preference for alcohol, methamphetamine or both. No mutant exhibited a difference in nicotine consumption or preference which was possibly confounded with saccharin. In the second round of prioritization, we employed a multivariate approach to identify outliers and performed validation using methamphetamine two-bottle choice and ethanol drinking-in-the-dark protocols. We identified 15/401 KO strains (3.7%, which included one gene from the first cohort) that differed most from controls for the predisposing phenotypes. 8 of 15 gene deletions (53%) affected intake or preference for alcohol, methamphetamine or both. Using multivariate and bioinformatic analyses, we observed multiple relations between predisposing behaviors and drug intake, revealing many distinct biobehavioral processes underlying these relationships. The set of mouse models identified in this study can be used to characterize these addiction-related processes further.
Collapse
Affiliation(s)
- Tyler A. Roy
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Jason A. Bubier
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Price E. Dickson
- Joan C Edwards School of MedicineMarshall UniversityHuntingtonWest VirginiaUSA
| | - Troy D. Wilcox
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Juliet Ndukum
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - James W. Clark
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Stacey J. Sukoff Rizzo
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
- School of MedicineUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - John C. Crabbe
- VA Portland Health Care SystemOregon Health & Science UniversityPortlandOregonUSA
| | - James M. Denegre
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Karen L. Svenson
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Robert E. Braun
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Vivek Kumar
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Stephen A. Murray
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | | | - Vivek M. Philip
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| | - Elissa J. Chesler
- Center for Addiction BiologyThe Jackson LaboratoryBar HarborMaineUSA
| |
Collapse
|
5
|
Kotredes KP, Pandey RS, Persohn S, Elderidge K, Burton CP, Miner EW, Haynes KA, Santos DFS, Williams SP, Heaton N, Ingraham CM, Lloyd C, Garceau D, O’Rourke R, Herrick S, Rangel-Barajas C, Maharjan S, Wang N, Sasner M, Lamb BT, Territo PR, Sukoff Rizzo SJ, Carter GW, Howell GR, Oblak AL. Characterizing Molecular and Synaptic Signatures in mouse models of Late-Onset Alzheimer's Disease Independent of Amyloid and Tau Pathology. bioRxiv 2023:2023.12.19.571985. [PMID: 38187716 PMCID: PMC10769232 DOI: 10.1101/2023.12.19.571985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2024]
Abstract
INTRODUCTION MODEL-AD is creating and distributing novel mouse models with humanized, clinically relevant genetic risk factors to more accurately mimic LOAD than commonly used transgenic models. METHODS We created the LOAD2 model by combining APOE4, Trem2*R47H, and humanized amyloid-beta. Mice aged up to 24 months were subjected to either a control diet or a high-fat/high-sugar diet (LOAD2+HFD) from two months of age. We assessed disease-relevant outcomes, including in vivo imaging, biomarkers, multi-omics, neuropathology, and behavior. RESULTS By 18 months, LOAD2+HFD mice exhibited cortical neuron loss, elevated insoluble brain Aβ42, increased plasma NfL, and altered gene/protein expression related to lipid metabolism and synaptic function. In vivo imaging showed age-dependent reductions in brain region volume and neurovascular uncoupling. LOAD2+HFD mice also displayed deficits in acquiring touchscreen-based cognitive tasks. DISCUSSION Collectively the comprehensive characterization of LOAD2+HFD mice reveal this model as important for preclinical studies that target features of LOAD independent of amyloid and tau.
Collapse
Affiliation(s)
- Kevin P. Kotredes
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
| | - Ravi S. Pandey
- The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, United States 06032
| | - Scott Persohn
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Kierra Elderidge
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Charles P Burton
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Ethan W. Miner
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Kathryn A. Haynes
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, 100 Technology Drive, Pittsburgh, PA Pittsburgh, PA, United States 15219
| | - Diogo Francisco S. Santos
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, 100 Technology Drive, Pittsburgh, PA Pittsburgh, PA, United States 15219
| | - Sean-Paul Williams
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, 100 Technology Drive, Pittsburgh, PA Pittsburgh, PA, United States 15219
| | - Nicholas Heaton
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, 100 Technology Drive, Pittsburgh, PA Pittsburgh, PA, United States 15219
| | - Cynthia M. Ingraham
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Christopher Lloyd
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
| | - Dylan Garceau
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
| | - Rita O’Rourke
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
| | - Sarah Herrick
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
| | - Claudia Rangel-Barajas
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 410 W. 10 St., HITS 4000, Indianapolis, IN, United States 46202
| | - Surendra Maharjan
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
- Department of Radiology & Imaging Sciences, Indiana University School of Medicine, 550 University Blvd, Indianapolis, IN, United States 46202
| | - Nian Wang
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
- Department of Radiology & Imaging Sciences, Indiana University School of Medicine, 550 University Blvd, Indianapolis, IN, United States 46202
| | - Michael Sasner
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
| | - Bruce T. Lamb
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, 410 W. 10 St., HITS 4000, Indianapolis, IN, United States 46202
| | - Paul R. Territo
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, 545 Barnhill Drive, Indianapolis, IN, United States 46202
| | - Stacey J. Sukoff Rizzo
- Department of Medicine, University of Pittsburgh Aging Institute, University of Pittsburgh School of Medicine, 100 Technology Drive, Pittsburgh, PA Pittsburgh, PA, United States 15219
| | - Gregory W. Carter
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
- The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, United States 06032
- Tufts University Graduate School of Biomedical Sciences, 136 Harrison Ave #813, Boston, MA, United States 02111
- Graduate School of Biomedical Sciences and Engineering, University of Maine, 5775 Stodder Hall, Orono, Maine, United States 04469
| | - Gareth R. Howell
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, United States, 04609
- Tufts University Graduate School of Biomedical Sciences, 136 Harrison Ave #813, Boston, MA, United States 02111
- Graduate School of Biomedical Sciences and Engineering, University of Maine, 5775 Stodder Hall, Orono, Maine, United States 04469
| | - Adrian L. Oblak
- Indiana University School of Medicine, 340 W 10 Street, Indianapolis, IN, United States 46202
- Stark Neurosciences Research Institute, 320 W 15 Street, Indianapolis, IN, United States 46202
- Department of Radiology & Imaging Sciences, Indiana University School of Medicine, 550 University Blvd, Indianapolis, IN, United States 46202
| |
Collapse
|
6
|
Quinney SK, Murugesh K, Oblak A, Onos KD, Sasner M, Greenwood AK, Woo KH, Rizzo SJS, Territo PR. STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's disease. Alzheimers Dement 2023; 19:5289-5295. [PMID: 37157089 DOI: 10.1002/alz.13108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 03/23/2023] [Accepted: 03/23/2023] [Indexed: 05/10/2023]
Abstract
We propose an unbiased methodology to rank compounds for advancement into comprehensive preclinical testing for Alzheimer's disease (AD). Translation of compounds to the clinic in AD has been hampered by poor predictive validity of models, compounds with limited pharmaceutical properties, and studies that lack rigor. To overcome this, MODEL-AD's Preclinical Testing Core developed a standardized pipeline for assessing efficacy in AD mouse models. We hypothesize that rank-ordering compounds based upon pharmacokinetic, efficacy, and toxicity properties in preclinical models will enhance successful translation to the clinic. Previously compound selection was based solely on physiochemical properties, with arbitrary cutoff limits, making ranking challenging. Since no gold standard exists for systematic prioritization, validating a selection criteria has remained elusive. The STOP-AD framework evaluates the drug-like properties to rank compounds for in vivo studies, and uses an unbiased approach that overcomes the validation limitation by performing Monte-Carlo simulations. HIGHLIGHTS: Promising preclinical studies for AD drugs have not translated to clinical success. Systematic assessment of AD drug candidates may increase clinical translatability. We describe a well-defined framework for compound selection with clear selection metrics.
Collapse
Affiliation(s)
- Sara K Quinney
- Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Kandasamy Murugesh
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Adrian Oblak
- Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | | | - Mike Sasner
- The Jackson Laboratory, Bar Harbor, Maine, USA
| | | | - Kara H Woo
- Sage Bionetworks, Seattle, Washington, USA
| | - Stacey J Sukoff Rizzo
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Paul R Territo
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
- Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA
| |
Collapse
|
7
|
Sasner M, Territo PR, Rizzo SJS. Meeting report of the annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease research. Alzheimers Dement 2023; 19:5284-5288. [PMID: 37070936 PMCID: PMC10582196 DOI: 10.1002/alz.13093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 03/21/2023] [Indexed: 04/19/2023]
Abstract
INTRODUCTION The second annual 5-day workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research was held October 7-11, 2019, at The Jackson Laboratory in Bar Harbor, Maine, USA, and included didactic lectures and hands-on training. Participants represented a broad range of research across the Alzheimer's disease (AD) field, and varied in career stages from trainees and early stage investigators to established faculty, with attendance from the United States, Europe, and Asia. METHODS In line with the National Institutes of Health (NIH) initiative on rigor and reproducibility, the workshop aimed to address training gaps in preclinical drug screening by providing participants with the skills and knowledge required to perform pharmacokinetic, pharmacodynamics, and preclinical efficacy experiments. RESULTS This innovative and comprehensive workshop provided training in fundamental skill sets for executing in vivo preclinical translational studies. DISCUSSION The success of this workship is expected to translate into practical skills that will enable the goals of improving preclinical to clinical translational studies for AD. HIGHLIGHTS Nearly all preclinical studies in animal models have failed to translate to successful efficacious medicines for Alzheimer's disease (AD) patients. While a wide variety of potential causes of these failures have been proposed,deficiencies in knowledge and best practices for translational research are not being sufficiently addressed by common training practices. Here we present proceedings from an annual NIA-sponsored workshop focused specifically on preclinical testing paradigms for AD translational research in animal models aimed at enabling improved preclinical to clinical translation for AD.
Collapse
Affiliation(s)
- Michael Sasner
- The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine, 04609, USA
| | - Paul R Territo
- Indiana University School of Medicine, Stark Neurosciences Research Institute, 320 W. 15th Street, 27 NB Suite 414, Indianapolis, Indiana, 46202-2266, USA
| | - Stacey J Sukoff Rizzo
- University of Pittsburgh School of Medicine – Aging Institute, 514A Bridgeside Point 1, 100 Technology Drive, Pittsburgh, PA, 15219, USA
| |
Collapse
|
8
|
Jesudason CD, Mason ER, Chu S, Oblak AL, Javens‐Wolfe J, Moussaif M, Durst G, Hipskind P, Beck DE, Dong J, Amarasinghe O, Zhang Z, Hamdani AK, Singhal K, Mesecar AD, Souza S, Jacobson M, Salvo JD, Soni DM, Kandasamy M, Masters AR, Quinney SK, Doolen S, Huhe H, Rizzo SJS, Lamb BT, Palkowitz AD, Richardson TI. SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease. Alzheimers Dement (N Y) 2023; 9:e12429. [PMID: 38023622 PMCID: PMC10655782 DOI: 10.1002/trc2.12429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 08/29/2023] [Accepted: 09/17/2023] [Indexed: 12/01/2023]
Abstract
INTRODUCTION The risk of developing Alzheimer's disease is associated with genes involved in microglial function. Inositol polyphosphate-5-phosphatase (INPP5D), which encodes Src homology 2 (SH2) domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1), is a risk gene expressed in microglia. Because SHIP1 binds receptor immunoreceptor tyrosine-based inhibitory motifs (ITIMs), competes with kinases, and converts PI(3,4,5)P3 to PI(3,4)P2, it is a negative regulator of microglia function. Validated inhibitors are needed to evaluate SHIP1 as a potential therapeutic target. METHODS We identified inhibitors and screened the enzymatic domain of SHIP1. A protein construct containing two domains was used to evaluate enzyme inhibitor potency and selectivity versus SHIP2. Inhibitors were tested against a construct containing all ordered domains of the human and mouse proteins. A cellular thermal shift assay (CETSA) provided evidence of target engagement in cells. Phospho-AKT levels provided further evidence of on-target pharmacology. A high-content imaging assay was used to study the pharmacology of SHIP1 inhibition while monitoring cell health. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties were evaluated to select a compound suitable for in vivo studies. RESULTS SHIP1 inhibitors displayed a remarkable array of activities and cellular pharmacology. Inhibitory potency was dependent on the protein construct used to assess enzymatic activity. Some inhibitors failed to engage the target in cells. Inhibitors that were active in the CETSA consistently destabilized the protein and reduced pAKT levels. Many SHIP1 inhibitors were cytotoxic either at high concentration due to cell stress or they potently induced cell death depending on the compound and cell type. One compound activated microglia, inducing phagocytosis at concentrations that did not result in significant cell death. A pharmacokinetic study demonstrated brain exposures in mice upon oral administration. DISCUSSION 3-((2,4-Dichlorobenzyl)oxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) pyridine activated primary mouse microglia and demonstrated exposures in mouse brain upon oral dosing. Although this compound is our recommended chemical probe for investigating the pharmacology of SHIP1 inhibition at this time, further optimization is required for clinical studies. Highlights Cellular thermal shift assay (CETSA) and signaling (pAKT) assays were developed to provide evidence of src homology 2 (SH2) domain-contaning inositol phosphatase 1 (SHIP1) target engagement and on-target activity in cellular assays.A phenotypic high-content imaging assay with simultaneous measures of phagocytosis, cell number, and nuclear intensity was developed to explore cellular pharmacology and monitor cell health.SHIP1 inhibitors demonstrate a wide range of activity and cellular pharmacology, and many reported inhibitors are cytotoxic.The chemical probe 3-((2,4-dichlorobenzyl)oxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) pyridine is recommended to explore SHIP1 pharmacology.
Collapse
Affiliation(s)
| | - Emily R. Mason
- Indiana University School of MedicineIndianapolisIndianaUSA
| | - Shaoyou Chu
- Indiana University School of MedicineIndianapolisIndianaUSA
| | - Adrian L. Oblak
- Indiana University School of MedicineIndianapolisIndianaUSA
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | | | | - Daniel E. Beck
- Institute for Drug DiscoveryPurdue UniversityWest LafayetteIndianaUSA
| | - Jiajun Dong
- Department of Medicinal Chemistry and Molecular PharmacologyPurdue UniversityWest LafayetteIndianaUSA
| | - Ovini Amarasinghe
- Department of Medicinal Chemistry and Molecular PharmacologyPurdue UniversityWest LafayetteIndianaUSA
| | - Zhong‐Yin Zhang
- Institute for Drug DiscoveryPurdue UniversityWest LafayetteIndianaUSA
- Department of Medicinal Chemistry and Molecular PharmacologyPurdue UniversityWest LafayetteIndianaUSA
| | - Adam K. Hamdani
- Department of BiochemistryPurdue UniversityWest LafayetteIndianaUSA
| | - Kratika Singhal
- Department of BiochemistryPurdue UniversityWest LafayetteIndianaUSA
| | | | | | | | | | - Disha M. Soni
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | - Sara K Quinney
- Indiana University School of MedicineIndianapolisIndianaUSA
| | - Suzanne Doolen
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Hasi Huhe
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | - Bruce T. Lamb
- Indiana University School of MedicineIndianapolisIndianaUSA
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
| | - Alan D. Palkowitz
- Indiana University School of MedicineIndianapolisIndianaUSA
- Indiana Biosciences Research InstituteIndianapolisIndianaUSA
| | - Timothy I. Richardson
- Indiana University School of MedicineIndianapolisIndianaUSA
- Stark Neurosciences Research InstituteIndiana University School of MedicineIndianapolisIndianaUSA
- Indiana Biosciences Research InstituteIndianapolisIndianaUSA
| |
Collapse
|
9
|
Roy TA, Bubier JA, Dickson PE, Wilcox TD, Ndukum J, Clark JW, Rizzo SJS, Crabbe JC, Denegre JM, Svenson KL, Braun RE, Kumar V, Murray SA, White JK, Philip VM, Chesler EJ. DISCOVERY AND VALIDATION OF GENES DRIVING DRUG-INTAKE AND RELATED BEHAVIORAL TRAITS IN MICE. bioRxiv 2023:2023.07.09.548280. [PMID: 37503148 PMCID: PMC10369854 DOI: 10.1101/2023.07.09.548280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
Substance use disorders (SUDs) are heritable disorders characterized by compulsive drug use, but the biological mechanisms driving addiction remain largely unknown. Genetic correlations reveal that predisposing drug-naïve phenotypes, including anxiety, depression, novelty preference, and sensation seeking, are predictive of drug-use phenotypes, implicating shared genetic mechanisms. Because of this relationship, high-throughput behavioral screening of predictive phenotypes in knockout (KO) mice allows efficient discovery of genes likely to be involved in drug use. We used this strategy in two rounds of screening in which we identified 33 drug-use candidate genes and ultimately validated the perturbation of 22 of these genes as causal drivers of substance intake. In our initial round of screening, we employed the two-bottle-choice paradigms to assess alcohol, methamphetamine, and nicotine intake. We identified 19 KO strains that were extreme responders on at least one predictive phenotype. Thirteen of the 19 gene deletions (68%) significantly affected alcohol use three methamphetamine use, and two both. In the second round of screening, we employed a multivariate approach to identify outliers and performed validation using methamphetamine two-bottle choice and ethanol drinking-in-the-dark protocols. We identified 15 KO strains that were extreme responders across the predisposing drug-naïve phenotypes. Eight of the 15 gene deletions (53%) significantly affected intake or preference for three alcohol, eight methamphetamine or three both (3). We observed multiple relations between predisposing behaviors and drug intake, revealing many distinct biobehavioral processes underlying these relationships. The set of mouse models identified in this study can be used to characterize these addiction-related processes further.
Collapse
Affiliation(s)
| | | | - Price E. Dickson
- Joan C Edwards School of Medicine, Marshall University Huntington, WV
| | | | | | | | - Stacey J. Sukoff Rizzo
- The Jackson Laboratory, Bar Harbor, ME
- University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - John C. Crabbe
- Oregon Health & Science University and VA Portland Health Care System, Portland, OR
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Sukoff Rizzo SJ, Homanics G, Schaeffer DJ, Schaeffer L, Park JE, Oluoch J, Zhang T, Haber A, Seyfried NT, Paten B, Greenwood A, Murai T, Choi SH, Huhe H, Kofler J, Strick PL, Carter GW, Silva AC. Bridging the rodent to human translational gap: Marmosets as model systems for the study of Alzheimer's disease. Alzheimers Dement (N Y) 2023; 9:e12417. [PMID: 37614242 PMCID: PMC10442521 DOI: 10.1002/trc2.12417] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 06/21/2023] [Accepted: 07/31/2023] [Indexed: 08/25/2023]
Abstract
Introduction Our limited understanding of the mechanisms that trigger the emergence of Alzheimer's disease (AD) has contributed to the lack of interventions that stop, prevent, or fully treat this disease. We believe that the development of a non-human primate model of AD will be an essential step toward overcoming limitations of other model systems and is crucial for investigating primate-specific mechanisms underlying the cellular and molecular root causes of the pathogenesis and progression of AD. Methods A new consortium has been established with funding support from the National Institute on Aging aimed at the generation, characterization, and validation of Marmosets As Research Models of AD (MARMO-AD). This consortium will study gene-edited marmoset models carrying genetic risk for AD and wild-type genetically diverse aging marmosets from birth throughout their lifespan, using non-invasive longitudinal assessments. These include characterizing the genetic, molecular, functional, behavioral, cognitive, and pathological features of aging and AD. Results The consortium successfully generated viable founders carrying PSEN1 mutations in C410Y and A426P using CRISPR/Cas9 approaches, with germline transmission demonstrated in the C410Y line. Longitudinal characterization of these models, their germline offspring, and normal aging outbred marmosets is ongoing. All data and resources from this consortium will be shared with the greater AD research community. Discussion By establishing marmoset models of AD, we will be able to investigate primate-specific cellular and molecular root causes that underlie the pathogenesis and progression of AD, overcome limitations of other model organisms, and support future translational studies to accelerate the pace of bringing therapies to patients.
Collapse
Affiliation(s)
| | - Gregg Homanics
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | - Lauren Schaeffer
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Jung Eun Park
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Julia Oluoch
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Tingting Zhang
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | | | - Benedict Paten
- University of California Santa Cruz Genomics InstituteUniversity of California Santa CruzSanta CruzCaliforniaUSA
| | | | - Takeshi Murai
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Sang Ho Choi
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Hasi Huhe
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Julia Kofler
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | - Peter L. Strick
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | - Afonso C. Silva
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| |
Collapse
|
11
|
Sukoff Rizzo SJ, Finkel T, Greenspan SL, Resnick NM, Brach JS. Speaking the Same Language: Team Science Approaches in Aging Research for Integrating Basic and Translational Science With Clinical Practice. Innov Aging 2023; 7:igad035. [PMID: 37213324 PMCID: PMC10198772 DOI: 10.1093/geroni/igad035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Indexed: 05/23/2023] Open
Abstract
Research on aging is at an important inflection point, where the insights accumulated over the last 2 decades in the basic biology of aging are poised to be translated into new interventions to promote health span and improve longevity. Progress in the basic science of aging is increasingly influencing medical practice, and the application and translation of geroscience require seamless integration of basic, translational, and clinical researchers. This includes the identification of new biomarkers, novel molecular targets as potential therapeutic agents, and translational in vivo studies to assess the potential efficacy of new interventions. To facilitate the required dialog between basic, translational, and clinical investigators, a multidisciplinary approach is essential and requires the collaborative expertise of investigators spanning molecular and cellular biology, neuroscience, physiology, animal models, physiologic and metabolic processes, pharmacology, genetics, and high-throughput drug screening approaches. In an effort to better enable the cross-talk of investigators across the broad spectrum of aging-related research disciplines, a goal of our University of Pittsburgh Claude D. Pepper Older Americans Independence Center has been to reduce the barriers to collaborative interactions by promoting a common language through team science. The culmination of these efforts will ultimately accelerate the ability to conduct first-in-human clinical trials of novel agents to extend health span and life span.
Collapse
Affiliation(s)
- Stacey J Sukoff Rizzo
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Toren Finkel
- Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Susan L Greenspan
- Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Neil M Resnick
- Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Jennifer S Brach
- Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
- Department of Physical Therapy, School of Health and Rehabilitation Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
12
|
Rizzo SJS. The essential role of animal models in the advancement of our understanding of human behaviors: A Commentary on the Special issue on the 30th Anniversary of the International Behavioral Neuroscience Society (IBNS). Neurosci Biobehav Rev 2023; 149:105182. [PMID: 37076055 DOI: 10.1016/j.neubiorev.2023.105182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/12/2023] [Accepted: 04/13/2023] [Indexed: 04/21/2023]
Affiliation(s)
- Stacey J Sukoff Rizzo
- Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Geriatric Medicine - Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
| |
Collapse
|
13
|
Oblak AL, Kotredes KP, Ingraham C, Territo PR, Rizzo SJS, Carter GW, Sasner M, Howell GR, Lamb BT. The role of Abca7 in late‐onset Alzheimer’s disease animal models. Alzheimers Dement 2022. [DOI: 10.1002/alz.067665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Adrian L Oblak
- Stark Neurosciences Research Institute, Indiana University School of Medicine Indianapolis IN USA
- Indiana University School of Medicine Indianapolis IN USA
| | | | - Cynthia Ingraham
- Indiana University, Stark Neurosciences Research Institute Indianapolis IN USA
| | - Paul R Territo
- Stark Neurosciences Research Institute, Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | - Bruce T Lamb
- Stark Neurosciences Research Institute, Indiana University School of Medicine Indianapolis IN USA
- Indiana University School of Medicine Indianapolis IN USA
| | | |
Collapse
|
14
|
Richardson TI, Jesudason CD, Lobb KL, Durst GL, Clayton B, Massey SM, Beck DE, Zhang Z, Dong J, Lin J, Miao J, Putt KS, Mesecar AD, Hamdani AK, Lendy EK, Souza S, Jacobson M, Salvo JD, Chu S, Mason ER, Oblak AL, Soni D, Quinney SK, Silva LL, Kandasamy M, Masters AR, Rizzo SJS, Doolen S, Huang K, Zhang J, Lamb BT, Palkowitz AD. A Target Enablement Package for the Inhibition of SHIP1 as a Therapeutic Strategy for the Treatment of Alzheimer’s Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.068781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Shaoyou Chu
- Indiana University School of Medicine Indianapolis IN USA
| | - Emily R Mason
- Indiana University School of Medicine Indianapolis IN USA
| | - Adrian L Oblak
- Indiana University School of Medicine Indianapolis IN USA
| | - Disha Soni
- Indiana University School of Medicine Indianapolis IN USA
| | - Sara K Quinney
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | - Suzanne Doolen
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Kun Huang
- Indiana University School of Medicine Indianapolis IN USA
| | - Jie Zhang
- Indiana University School of Medicine Indianapolis IN USA
| | - Bruce T Lamb
- Indiana University School of Medicine Indianapolis IN USA
| | | |
Collapse
|
15
|
Territo PR, Quinney SK, Masters AR, Haynes KA, Cope ZA, Little G, Williams S, Meyer JA, Peters J, Figueiredo L, Persohn SC, Bedwell AA, Eldridge K, Speedy R, Seyfried NT, Onos KD, Sasner M, Howell GR, Carter GW, Oblak AL, Lamb BT, Rizzo SJS. Pharmacodynamics Assessment of Aducanumab in 5XFAD mice: A MODEL‐AD PTC Study. Alzheimers Dement 2022. [DOI: 10.1002/alz.064606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Paul R Territo
- Indiana University School of Medicine Indianapolis IN USA
| | - Sara K Quinney
- Indiana University School of Medicine Indianapolis IN USA
| | | | - Katy A Haynes
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | - Gabriela Little
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | - Jill A Meyer
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | - Amanda A Bedwell
- Stark Neurosciences Research Institute, Indiana University School of Medicine Indianapolis IN USA
| | | | - Rachael Speedy
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | | | - Adrian L Oblak
- Indiana University School of Medicine Indianapolis IN USA
| | - Bruce T Lamb
- Indiana University School of Medicine Indianapolis IN USA
| | | |
Collapse
|
16
|
Rizzo SJS, Choi S, Huhe H, Kofler J, Schaeffer D, Murai T, Hachem S, Karavolis M, Mou Y, Ha S, Carter GW, Park JE, Homanics GE, Strick PL, Silva AC. Differential brain expression of 3R and 4R Tau isoforms in aging wild‐type and young genetically engineered PSEN1 mutant marmosets. Alzheimers Dement 2022. [DOI: 10.1002/alz.069206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Sang‐Ho Choi
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Hasi Huhe
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Julia Kofler
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - David Schaeffer
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Takeshi Murai
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | | | - Yongshan Mou
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Seung‐Kwon Ha
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | - Jung Eun Park
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | - Peter L Strick
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Afonso C Silva
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| |
Collapse
|
17
|
Elk KJ, Garceau D, Oblak AL, Pandey RS, Carter GW, Ferron G, Linehan ST, Ragan T, Little G, Williams S, Rizzo SJS, Lin S, Datta SR, Sasner M. Comparative characterization of 5XFAD and hAbeta
SAA
mouse models of familial AD. Alzheimers Dement 2022. [DOI: 10.1002/alz.067648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | - Adrian L Oblak
- Indiana University School of Medicine Indianapolis IN USA
| | - Ravi S Pandey
- The Jackson Laboratory for Genomic Medicine Farmington CT USA
| | | | | | | | | | - Gabriela Little
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | | | | | | | | | | |
Collapse
|
18
|
Schoenrock SA, Gagnon L, Olson A, Leonardo M, Philip VM, He H, Reinholdt LG, Sukoff Rizzo SJ, Jentsch JD, Chesler EJ, Tarantino LM. The collaborative cross strains and their founders vary widely in cocaine-induced behavioral sensitization. Front Behav Neurosci 2022; 16:886524. [PMID: 36275853 PMCID: PMC9580558 DOI: 10.3389/fnbeh.2022.886524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 08/01/2022] [Indexed: 07/25/2023] Open
Abstract
Cocaine use and overdose deaths attributed to cocaine have increased significantly in the United States in the last 10 years. Despite the prevalence of cocaine use disorder (CUD) and the personal and societal problems it presents, there are currently no approved pharmaceutical treatments. The absence of treatment options is due, in part, to our lack of knowledge about the etiology of CUDs. There is ample evidence that genetics plays a role in increasing CUD risk but thus far, very few risk genes have been identified in human studies. Genetic studies in mice have been extremely useful for identifying genetic loci and genes, but have been limited to very few genetic backgrounds, leaving substantial phenotypic, and genetic diversity unexplored. Herein we report the measurement of cocaine-induced behavioral sensitization using a 19-day protocol that captures baseline locomotor activity, initial locomotor response to an acute exposure to cocaine and locomotor sensitization across 5 exposures to the drug. These behaviors were measured in 51 genetically diverse Collaborative Cross (CC) strains along with their inbred founder strains. The CC was generated by crossing eight genetically diverse inbred strains such that each inbred CC strain has genetic contributions from each of the founder strains. Inbred CC mice are infinitely reproducible and provide a stable, yet diverse genetic platform on which to study the genetic architecture and genetic correlations among phenotypes. We have identified significant differences in cocaine locomotor sensitivity and behavioral sensitization across the panel of CC strains and their founders. We have established relationships among cocaine sensitization behaviors and identified extreme responding strains that can be used in future studies aimed at understanding the genetic, biological, and pharmacological mechanisms that drive addiction-related behaviors. Finally, we have determined that these behaviors exhibit relatively robust heritability making them amenable to future genetic mapping studies to identify addiction risk genes and genetic pathways that can be studied as potential targets for the development of novel therapeutics.
Collapse
Affiliation(s)
- Sarah A. Schoenrock
- Department of Genetics, School of Medicine, Chapel Hill, NC, United States
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
| | - Leona Gagnon
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Ashley Olson
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Michael Leonardo
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Vivek M. Philip
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Hao He
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Laura G. Reinholdt
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Stacey J. Sukoff Rizzo
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | - James D. Jentsch
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- Department of Psychology, Binghamton University, Binghamton, NY, United States
| | - Elissa J. Chesler
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Lisa M. Tarantino
- Department of Genetics, School of Medicine, Chapel Hill, NC, United States
- Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| |
Collapse
|
19
|
Onos KD, Quinney SK, Jones DR, Masters AR, Pandey R, Keezer KJ, Biesdorf C, Metzger IF, Meyers JA, Peters J, Persohn SC, McCarthy BP, Bedwell AA, Figueiredo LL, Cope ZA, Sasner M, Howell GR, Williams HM, Oblak AL, Lamb BT, Carter GW, Rizzo SJS, Territo PR. Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study. Alzheimers Dement (N Y) 2022; 8:e12329. [PMID: 36016830 PMCID: PMC9398229 DOI: 10.1002/trc2.12329] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 04/06/2022] [Accepted: 06/01/2022] [Indexed: 11/08/2022]
Abstract
Introduction Hyperexcitability and epileptiform activity are commonplace in Alzheimer's disease (AD) patients and associated with impaired cognitive function. The anti-seizure drug levetiracetam (LEV) is currently being evaluated in clinical trials for ability to reduce epileptiform activity and improve cognitive function in AD. The purpose of our studies was to establish a pharmacokinetic/pharmacodynamic (PK/PD) relationship with LEV in an amyloidogenic mouse model of AD to enable predictive preclinical to clinical translation, using the rigorous preclinical testing pipeline of the Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease Preclinical Testing Core. Methods A multi-tier approach was applied that included quality assurance and quality control of the active pharmaceutical ingredient, PK/PD modeling, positron emission tomography/magnetic resonance imaging (PET/MRI), functional outcomes, and transcriptomics. 5XFAD mice were treated chronically with LEV for 3 months at doses in line with those allometrically scaled to the clinical dose range. Results Pharmacokinetics of LEV demonstrated sex differences in Cmax, AUC0-∞, and CL/F, and a dose dependence in AUC0-∞. After chronic dosing at 10, 30, 56 mg/kg, PET/MRI tracer 18F-AV45, and 18F-fluorodeoxyglucose (18F-FDG) showed specific regional differences with treatment. LEV did not significantly improve cognitive outcomes. Transcriptomics performed by nanoString demonstrated drug- and dose-related changes in gene expression relevant to human brain regions and pathways congruent with changes in 18F-FDG uptake. Discussion This study represents the first report of PK/PD assessment of LEV in 5XFAD mice. Overall, these results highlighted non-linear kinetics based on dose and sex. Plasma concentrations of the 10 mg/kg dose in 5XFAD overlapped with human plasma concentrations used for studies of mild cognitive impairment, while the 30 and 56 mg/kg doses were reflective of doses used to treat seizure activity. Post-treatment gene expression analysis demonstrated LEV dose-related changes in immune function and neuronal-signaling pathways relevant to human AD, and aligned with regional 18F-FDG uptake. Overall, this study highlights the importance of PK/PD relationships in preclinical studies to inform clinical study design. Highlights Significant sex differences in pharmacokinetics of levetiracetam were observed in 5XFAD mice.Plasma concentrations of 10 mg/kg levetiracetam dose in 5XFAD overlapped with human plasma concentration used in the clinic.Drug- and dose-related differences in gene expression relevant to human brain regions and pathways were also similar to brain region-specific changes in 18F-fluorodeoxyglucose uptake.
Collapse
Affiliation(s)
| | | | - David R. Jones
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | | - Carla Biesdorf
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | - Jill A. Meyers
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | | | | | | | | | | | | | | | | - Bruce T. Lamb
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | |
Collapse
|
20
|
Oblak AL, Cope ZA, Quinney SK, Pandey RS, Biesdorf C, Masters AR, Onos KD, Haynes L, Keezer KJ, Meyer JA, Peters JS, Persohn SA, Bedwell AA, Eldridge K, Speedy R, Little G, Williams S, Noarbe B, Obenaus A, Sasner M, Howell GR, Carter GW, Williams H, Lamb BT, Territo PR, Sukoff Rizzo SJ. Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice. Alzheimers Dement (N Y) 2022; 8:e12317. [PMID: 35846156 PMCID: PMC9281365 DOI: 10.1002/trc2.12317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 03/31/2022] [Accepted: 05/24/2022] [Indexed: 11/12/2022]
Abstract
Introduction Alzheimer's disease (AD) is the most common form of dementia. Beta-secretase (BACE) inhibitors have been proposed as potential therapeutic interventions; however, initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease. Whether BACE inhibition may have efficacy when administered prophylactically in the early stages of AD has been under-investigated. The present studies aimed to evaluate prophylactic treatment of the BACE inhibitor verubecestat in an AD mouse model using the National Institute on Aging (NIA) resources of the Model Organism Development for Late-Onset Alzheimer's Disease (MODEL-AD) Preclinical Testing Core (PTC) Drug Screening Pipeline. Methods 5XFAD mice were administered verubecestat ad libitum in chow from 3 to 6 months of age, prior to the onset of significant disease pathology. Following treatment (6 months of age), in vivo imaging was conducted with 18F-florbetapir (AV-45/Amyvid) (18F-AV45) and 18-FDG (fluorodeoxyglucose)-PET (positron emission tomography)/MRI (magnetic resonance imaging), brain and plasma amyloid beta (Aβ) were measured, and the clinical and behavioral characteristics of the mice were assessed and correlated with the pharmacokinetic data. Results Prophylactic verubecestat treatment resulted in dose- and region-dependent attenuations of 18F-AV45 uptake in male and female 5XFAD mice. Plasma Aβ40 and Aβ42 were also dose-dependently attenuated with treatment. Across the dose range evaluated, side effects including coat color changes and motor alterations were reported, in the absence of cognitive improvement or changes in 18F-FDG uptake. Discussion Prophylactic treatment with verubecestat resulted in attenuated amyloid plaque deposition when treatment was initiated prior to significant pathology in 5XFAD mice. At the same dose range effective at attenuating Aβ levels, verubecestat produced side effects in the absence of improvements in cognitive function. Taken together these data demonstrate the rigorous translational approaches of the MODEL-AD PTC for interrogating potential therapeutics and provide insight into the limitations of verubecestat as a prophylactic intervention for early-stage AD.
Collapse
Affiliation(s)
| | - Zackary A. Cope
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | - Ravi S. Pandey
- The Jackson Laboratory for Genomic MedicineFarmingtonConnecticutUSA
- The Jackson LaboratoryBar HarborMaineUSA
| | - Carla Biesdorf
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | | | | - Jill A. Meyer
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | | | | | | | - Rachael Speedy
- Indiana University School of MedicineIndianapolisIndianaUSA
| | - Gabriela Little
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
| | | | | | | | | | - Gareth R. Howell
- The Jackson Laboratory for Genomic MedicineFarmingtonConnecticutUSA
- University of CaliforniaIrvineCaliforniaUSA
| | - Gregory W. Carter
- The Jackson Laboratory for Genomic MedicineFarmingtonConnecticutUSA
- University of CaliforniaIrvineCaliforniaUSA
| | | | - Bruce T. Lamb
- Indiana University School of MedicineIndianapolisIndianaUSA
| | | | - Stacey J. Sukoff Rizzo
- University of Pittsburgh School of MedicinePittsburghPennsylvaniaUSA
- The Jackson LaboratoryBar HarborMaineUSA
| |
Collapse
|
21
|
Muratoglu SC, Charette MF, Galis ZS, Greenstein AS, Daugherty A, Joutel A, Kozel BA, Wilcock DM, Collins EC, Sorond FA, Howell GR, Hyacinth HI, Lloyd KKC, Stenmark KR, Boehm M, Kahn ML, Corriveau R, Wells S, Bussey TJ, Sukoff Rizzo SJ, Iruela-Arispe ML. Perspectives on Cognitive Phenotypes and Models of Vascular Disease. Arterioscler Thromb Vasc Biol 2022; 42:831-838. [PMID: 35510549 PMCID: PMC9233038 DOI: 10.1161/atvbaha.122.317395] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Clinical investigations have established that vascular-associated medical conditions are significant risk factors for various kinds of dementia. And yet, we are unable to associate certain types of vascular deficiencies with specific cognitive impairments. The reasons for this are many, not the least of which are that most vascular disorders are multi-factorial and the development of vascular dementia in humans is often a multi-year or multi-decade progression. To better study vascular disease and its underlying causes, the National Heart, Lung, and Blood Institute of the National Institutes of Health has invested considerable resources in the development of animal models that recapitulate various aspects of human vascular disease. Many of these models, mainly in the mouse, are based on genetic mutations, frequently using single-gene mutations to examine the role of specific proteins in vascular function. These models could serve as useful tools for understanding the association of specific vascular signaling pathways with specific neurological and cognitive impairments related to dementia. To advance the state of the vascular dementia field and improve the information sharing between the vascular biology and neurobehavioral research communities, National Heart, Lung, and Blood Institute convened a workshop to bring in scientists from these knowledge domains to discuss the potential utility of establishing a comprehensive phenotypic cognitive assessment of a selected set of existing mouse models, representative of the spectrum of vascular disorders, with particular attention focused on age, sex, and rigor and reproducibility. The workshop highlighted the potential of associating well-characterized vascular disease models, with validated cognitive outcomes, that can be used to link specific vascular signaling pathways with specific cognitive and neurobehavioral deficits.
Collapse
Affiliation(s)
- Selen C Muratoglu
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (S.C.M., M.F.C., Z.S.G.)
| | - Marc F Charette
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (S.C.M., M.F.C., Z.S.G.)
| | - Zorina S Galis
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (S.C.M., M.F.C., Z.S.G.)
| | - Adam S Greenstein
- Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom (A.S.G.)
| | - Alan Daugherty
- Saha Cardiovascular Research Center (A.D.), University of Kentucky, Lexington
| | - Anne Joutel
- Institute of Psychiatry and Neurosciences of Paris, INSERM U1266, Université Paris Descartes, France (A.J.)
| | - Beth A Kozel
- Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (B.A.K., M.B.)
| | - Donna M Wilcock
- Sanders-Brown Center on Aging, Department of Neuroscience (D.M.W.), University of Kentucky, Lexington
| | | | - Farzaneh A Sorond
- Division of Stroke and Neurocritical Care, Northwestern University Feinberg School of Medicine, Chicago, IL (F.A.S.)
| | - Gareth R Howell
- The Jackson Laboratory, Bar Harbor, ME (G.R.H.)
- Graduate Program of Genetics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA (G.R.H.)
| | - Hyacinth I Hyacinth
- Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH (H.I.H.)
| | - Kent K C Lloyd
- Mutant Mouse Resource and Research Center (MMRRC) at the University of California, Davis (K.K.C.L.)
| | - Kurt R Stenmark
- Developmental Lung Biology and Cardiovascular Pulmonary Research Laboratories, University of Colorado, Denver (K.R.S.)
| | - Manfred Boehm
- Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (B.A.K., M.B.)
| | - Mark L Kahn
- Department of Medicine and Cardiovascular Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia (M.L.K.)
| | - Roderick Corriveau
- National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (R.C.)
| | - Sara Wells
- Mary Lyon Centre, Harwell Campus, MRC Harwell Institute, Oxfordshire, United Kingdom (S.W.)
| | - Timothy J Bussey
- Translational Neuroscience Group, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada (T.J.B.)
| | - Stacey J Sukoff Rizzo
- Department of Medicine-Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA (S.J.S.R.)
| | - M Luisa Iruela-Arispe
- Department of Cell and Developmental Biology, Northwestern University, Feinberg School of Medicine, Chicago, IL (M.L.I.-A.)
| |
Collapse
|
22
|
Oblak AL, Kotredes KP, Pandey RS, Reagan AM, Ingraham C, Perkins B, Lloyd C, Baker D, Lin PB, Soni DM, Tsai AP, Persohn SA, Bedwell AA, Eldridge K, Speedy R, Meyer JA, Peters JS, Figueiredo LL, Sasner M, Territo PR, Sukoff Rizzo SJ, Carter GW, Lamb BT, Howell GR. Plcg2M28L Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer’s Disease-Relevant Phenotypes in Mice. Front Aging Neurosci 2022; 14:886575. [PMID: 35813947 PMCID: PMC9263289 DOI: 10.3389/fnagi.2022.886575] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 05/09/2022] [Indexed: 11/30/2022] Open
Abstract
Obesity is recognized as a significant risk factor for Alzheimer’s disease (AD). Studies have supported the notion that obesity accelerates AD-related pathophysiology in mouse models of AD. The majority of studies, to date, have focused on the use of early-onset AD models. Here, we evaluate the impact of genetic risk factors on late-onset AD (LOAD) in mice fed with a high fat/high sugar diet (HFD). We focused on three mouse models created through the IU/JAX/PITT MODEL-AD Center. These included a combined risk model with APOE4 and a variant in triggering receptor expressed on myeloid cells 2 (Trem2R47H). We have termed this model, LOAD1. Additional variants including the M28L variant in phospholipase C Gamma 2 (Plcg2M28L) and the 677C > T variant in methylenetetrahydrofolate reductase (Mthfr677C >T) were engineered by CRISPR onto LOAD1 to generate LOAD1.Plcg2M28L and LOAD1.Mthfr677C >T. At 2 months of age, animals were placed on an HFD that induces obesity or a control diet (CD), until 12 months of age. Throughout the study, blood was collected to assess the levels of cholesterol and glucose. Positron emission tomography/computed tomography (PET/CT) was completed prior to sacrifice to image for glucose utilization and brain perfusion. After the completion of the study, blood and brains were collected for analysis. As expected, animals fed a HFD, showed a significant increase in body weight compared to those fed a CD. Glucose increased as a function of HFD in females only with cholesterol increasing in both sexes. Interestingly, LOAD1.Plcg2M28L demonstrated an increase in microglia density and alterations in regional brain glucose and perfusion on HFD. These changes were not observed in LOAD1 or LOAD1.Mthfr677C >T animals fed with HFD. Furthermore, LOAD1.Plcg2M28L but not LOAD1.Mthfr677C >T or LOAD1 animals showed transcriptomics correlations with human AD modules. Our results show that HFD affects the brain in a genotype-specific manner. Further insight into this process may have significant implications for the development of lifestyle interventions for the treatment of AD.
Collapse
Affiliation(s)
- Adrian L. Oblak
- Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
- *Correspondence: Adrian L. Oblak,
| | | | - Ravi S. Pandey
- The Jackson Laboratory, Bar Harbor, ME, United States
- Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
| | | | - Cynthia Ingraham
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Bridget Perkins
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Christopher Lloyd
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Deborah Baker
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Peter B. Lin
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Disha M. Soni
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Andy P. Tsai
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Scott A. Persohn
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Amanda A. Bedwell
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Kierra Eldridge
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Rachael Speedy
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Jill A. Meyer
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Johnathan S. Peters
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Lucas L. Figueiredo
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | | | - Paul R. Territo
- Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
- Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Stacey J. Sukoff Rizzo
- Department of Medicine, Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | | | - Bruce T. Lamb
- Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Radiology & Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indianapolis, IN, United States
| | - Gareth R. Howell
- The Jackson Laboratory, Bar Harbor, ME, United States
- Gareth R. Howell,
| |
Collapse
|
23
|
Cope ZA, Murai T, Sukoff Rizzo SJ. Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease. Front Aging Neurosci 2022; 14:805063. [PMID: 35250541 PMCID: PMC8891809 DOI: 10.3389/fnagi.2022.805063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 01/26/2022] [Indexed: 11/18/2022] Open
Abstract
Continually emerging data indicate that sub-clinical, non-convulsive epileptiform activity is not only prevalent in Alzheimer’s disease (AD) but is detectable early in the course of the disease and predicts cognitive decline in both humans and animal models. Epileptiform activity and other electroencephalographic (EEG) measures may hold powerful, untapped potential to improve the translational validity of AD-related biomarkers in model animals ranging from mice, to rats, and non-human primates. In this review, we will focus on studies of epileptiform activity, EEG slowing, and theta-gamma coupling in preclinical models, with particular focus on its role in cognitive decline and relevance to AD. Here, each biomarker is described in the context of the contemporary literature and recent findings in AD relevant animal models are discussed.
Collapse
|
24
|
Kotredes KP, Oblak A, Pandey RS, Lin PBC, Garceau D, Williams H, Uyar A, O'Rourke R, O'Rourke S, Ingraham C, Bednarczyk D, Belanger M, Cope Z, Foley KE, Logsdon BA, Mangravite LM, Sukoff Rizzo SJ, Territo PR, Carter GW, Sasner M, Lamb BT, Howell GR. Corrigendum: Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H. Front Aging Neurosci 2022; 14:857628. [PMID: 35197847 PMCID: PMC8859544 DOI: 10.3389/fnagi.2022.857628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 01/19/2022] [Indexed: 11/19/2022] Open
Affiliation(s)
| | - Adrian Oblak
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | - Peter Bor-Chian Lin
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | - Dylan Garceau
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Asli Uyar
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Rita O'Rourke
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Cynthia Ingraham
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | | | - Zackary Cope
- Department of Medicine—Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Kate E. Foley
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | | | - Stacey J. Sukoff Rizzo
- Department of Medicine—Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Paul R. Territo
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | | | - Bruce T. Lamb
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
- Bruce T. Lamb
| | - Gareth R. Howell
- The Jackson Laboratory, Bar Harbor, ME, United States
- *Correspondence: Gareth R. Howell
| |
Collapse
|
25
|
Carter GW, Howell GR, Lamb BT, Oblak AL, Rizzo SJS, Sasner M, Territo PR. Creating, characterizing, and validating the next generation of mouse models for late‐onset Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.049954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - Bruce T. Lamb
- Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis IN USA
| | - Adrian L Oblak
- Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis IN USA
| | | | | | - Paul R Territo
- Indiana University School of Medicine Indianapolis IN USA
| |
Collapse
|
26
|
Rizzo SJS, Homanics GE, Park JE, Silva AC, Strick PL. Establishing the marmoset as a non‐human primate model of Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.049952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - Jung Eun Park
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Afonso C Silva
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Peter L Strick
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| |
Collapse
|
27
|
Kotredes KP, Oblak AL, Preuss C, Pandey RS, Territo PR, Rizzo SJS, Carter GW, Sasner M, Howell GR, Lamb BT. LOAD2: A late‐onset Alzheimer’s disease mouse model expressing
APOEε4
,
Trem2*R47H
, and humanized amyloid‐beta. Alzheimers Dement 2021. [DOI: 10.1002/alz.056017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - Adrian L Oblak
- Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis IN USA
| | | | - Ravi S Pandey
- The Jackson Laboratory for Genomic Medicine Farmington CT USA
| | - Paul R Territo
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | - Bruce T. Lamb
- Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis IN USA
| | | |
Collapse
|
28
|
Bailey LS, Bagley JR, Dodd R, Olson A, Bolduc M, Philip VM, Reinholdt LG, Sukoff Rizzo SJ, Tarantino L, Gagnon L, Chesler EJ, Jentsch JD. Heritable variation in locomotion, reward sensitivity and impulsive behaviors in a genetically diverse inbred mouse panel. Genes Brain Behav 2021; 20:e12773. [PMID: 34672075 PMCID: PMC9044817 DOI: 10.1111/gbb.12773] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 09/14/2021] [Accepted: 09/15/2021] [Indexed: 12/13/2022]
Abstract
Drugs of abuse, including alcohol and stimulants like cocaine, produce effects that are subject to individual variability, and genetic variation accounts for at least a portion of those differences. Notably, research in both animal models and human subjects point toward reward sensitivity and impulsivity as being trait characteristics that predict relatively greater positive subjective responses to stimulant drugs. Here we describe use of the eight collaborative cross (CC) founder strains and 38 (reversal learning) or 10 (all other tests) CC strains to examine the heritability of reward sensitivity and impulsivity traits, as well as genetic correlations between these measures and existing addiction-related phenotypes. Strains were all tested for activity in an open field and reward sensitivity (intake of chocolate BOOST®). Mice were then divided into two counterbalanced groups and underwent reversal learning (impulsive action and waiting impulsivity) or delay discounting (impulsive choice). CC and founder mice show significant heritability for impulsive action, impulsive choice, waiting impulsivity, locomotor activity, and reward sensitivity, with each impulsive phenotype determined to be non-correlating, independent traits. This research was conducted within the broader, inter-laboratory effort of the Center for Systems Neurogenetics of Addiction (CSNA) to characterize CC and DO mice for multiple, cocaine abuse related traits. These data will facilitate the discovery of genetic correlations between predictive traits, which will then guide discovery of genes and genetic variants that contribute to addictive behaviors.
Collapse
Affiliation(s)
- Lauren S Bailey
- State University of New York - Binghamton University, Binghamton, New York, USA
| | - Jared R Bagley
- State University of New York - Binghamton University, Binghamton, New York, USA
| | - Rainy Dodd
- The Jackson Laboratory, Bar Harbor, Maine, USA
| | | | | | | | | | - Stacey J Sukoff Rizzo
- The Jackson Laboratory, Bar Harbor, Maine, USA
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Lisa Tarantino
- The Jackson Laboratory, Bar Harbor, Maine, USA
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | | | | | - James David Jentsch
- State University of New York - Binghamton University, Binghamton, New York, USA
- The Jackson Laboratory, Bar Harbor, Maine, USA
| |
Collapse
|
29
|
Kotredes KP, Oblak A, Pandey RS, Lin PBC, Garceau D, Williams H, Uyar A, O’Rourke R, O’Rourke S, Ingraham C, Bednarczyk D, Belanger M, Cope Z, Foley KE, Logsdon BA, Mangravite LM, Sukoff Rizzo SJ, Territo PR, Carter GW, Sasner M, Lamb BT, Howell GR. Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H. Front Aging Neurosci 2021; 13:735524. [PMID: 34707490 PMCID: PMC8544520 DOI: 10.3389/fnagi.2021.735524] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Accepted: 09/06/2021] [Indexed: 11/13/2022] Open
Abstract
Late-onset Alzheimer's disease (AD; LOAD) is the most common human neurodegenerative disease, however, the availability and efficacy of disease-modifying interventions is severely lacking. Despite exceptional efforts to understand disease progression via legacy amyloidogenic transgene mouse models, focus on disease translation with innovative mouse strains that better model the complexity of human AD is required to accelerate the development of future treatment modalities. LOAD within the human population is a polygenic and environmentally influenced disease with many risk factors acting in concert to produce disease processes parallel to those often muted by the early and aggressive aggregate formation in popular mouse strains. In addition to extracellular deposits of amyloid plaques and inclusions of the microtubule-associated protein tau, AD is also defined by synaptic/neuronal loss, vascular deficits, and neuroinflammation. These underlying processes need to be better defined, how the disease progresses with age, and compared to human-relevant outcomes. To create more translatable mouse models, MODEL-AD (Model Organism Development and Evaluation for Late-onset AD) groups are identifying and integrating disease-relevant, humanized gene sequences from public databases beginning with APOEε4 and Trem2*R47H, two of the most powerful risk factors present in human LOAD populations. Mice expressing endogenous, humanized APOEε4 and Trem2*R47H gene sequences were extensively aged and assayed using a multi-disciplined phenotyping approach associated with and relative to human AD pathology. Robust analytical pipelines measured behavioral, transcriptomic, metabolic, and neuropathological phenotypes in cross-sectional cohorts for progression of disease hallmarks at all life stages. In vivo PET/MRI neuroimaging revealed regional alterations in glycolytic metabolism and vascular perfusion. Transcriptional profiling by RNA-Seq of brain hemispheres identified sex and age as the main sources of variation between genotypes including age-specific enrichment of AD-related processes. Similarly, age was the strongest determinant of behavioral change. In the absence of mouse amyloid plaque formation, many of the hallmarks of AD were not observed in this strain. However, as a sensitized baseline model with many additional alleles and environmental modifications already appended, the dataset from this initial MODEL-AD strain serves an important role in establishing the individual effects and interaction between two strong genetic risk factors for LOAD in a mouse host.
Collapse
Affiliation(s)
| | - Adrian Oblak
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | - Peter Bor-Chian Lin
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | - Dylan Garceau
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Asli Uyar
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Rita O’Rourke
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Cynthia Ingraham
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | | | - Zackary Cope
- Department of Medicine—Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Kate E. Foley
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | | | - Stacey J. Sukoff Rizzo
- Department of Medicine—Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Paul R. Territo
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | | | | - Bruce T. Lamb
- Stark Neurosciences Research Institute, School of Medicine, Indiana University Bloomington, Indianapolis, IN, United States
| | | |
Collapse
|
30
|
Oblak AL, Lin PB, Kotredes KP, Pandey RS, Garceau D, Williams HM, Uyar A, O'Rourke R, O'Rourke S, Ingraham C, Bednarczyk D, Belanger M, Cope ZA, Little GJ, Williams SPG, Ash C, Bleckert A, Ragan T, Logsdon BA, Mangravite LM, Sukoff Rizzo SJ, Territo PR, Carter GW, Howell GR, Sasner M, Lamb BT. Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. Front Aging Neurosci 2021; 13:713726. [PMID: 34366832 DOI: 10.3389/fnagi.2021.71372] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/23/2021] [Indexed: 05/23/2023] Open
Abstract
The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used. There are numerous models that have been generated to study Alzheimer's disease (AD) and the underlying pathogenesis of the disease. While transgenic models have been instrumental in understanding AD mechanisms and risk factors, they are limited in the degree of characteristics displayed in comparison with AD in humans, and the full spectrum of AD effects has yet to be recapitulated in a single mouse model. The Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease (MODEL-AD) consortium was assembled by the National Institute on Aging (NIA) to develop more robust animal models of AD with increased relevance to human disease, standardize the characterization of AD mouse models, improve preclinical testing in animals, and establish clinically relevant AD biomarkers, among other aims toward enhancing the translational value of AD models in clinical drug design and treatment development. Here we have conducted a detailed characterization of the 5XFAD mouse, including transcriptomics, electroencephalogram, in vivo imaging, biochemical characterization, and behavioral assessments. The data from this study is publicly available through the AD Knowledge Portal.
Collapse
Affiliation(s)
- Adrian L Oblak
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Peter B Lin
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | - Ravi S Pandey
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Dylan Garceau
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Asli Uyar
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Rita O'Rourke
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Cynthia Ingraham
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | - Melisa Belanger
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | - Zackary A Cope
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | - Gabriela J Little
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | | | - Carl Ash
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Adam Bleckert
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
| | - Tim Ragan
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
| | | | | | | | - Paul R Territo
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | | | | | - Bruce T Lamb
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States
| |
Collapse
|
31
|
Oblak AL, Lin PB, Kotredes KP, Pandey RS, Garceau D, Williams HM, Uyar A, O'Rourke R, O'Rourke S, Ingraham C, Bednarczyk D, Belanger M, Cope ZA, Little GJ, Williams SPG, Ash C, Bleckert A, Ragan T, Logsdon BA, Mangravite LM, Sukoff Rizzo SJ, Territo PR, Carter GW, Howell GR, Sasner M, Lamb BT. Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. Front Aging Neurosci 2021; 13:713726. [PMID: 34366832 PMCID: PMC8346252 DOI: 10.3389/fnagi.2021.713726] [Citation(s) in RCA: 106] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/23/2021] [Indexed: 12/14/2022] Open
Abstract
The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used. There are numerous models that have been generated to study Alzheimer's disease (AD) and the underlying pathogenesis of the disease. While transgenic models have been instrumental in understanding AD mechanisms and risk factors, they are limited in the degree of characteristics displayed in comparison with AD in humans, and the full spectrum of AD effects has yet to be recapitulated in a single mouse model. The Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease (MODEL-AD) consortium was assembled by the National Institute on Aging (NIA) to develop more robust animal models of AD with increased relevance to human disease, standardize the characterization of AD mouse models, improve preclinical testing in animals, and establish clinically relevant AD biomarkers, among other aims toward enhancing the translational value of AD models in clinical drug design and treatment development. Here we have conducted a detailed characterization of the 5XFAD mouse, including transcriptomics, electroencephalogram, in vivo imaging, biochemical characterization, and behavioral assessments. The data from this study is publicly available through the AD Knowledge Portal.
Collapse
Affiliation(s)
- Adrian L Oblak
- Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States.,Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Peter B Lin
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | - Ravi S Pandey
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Dylan Garceau
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Asli Uyar
- The Jackson Laboratory, Bar Harbor, ME, United States
| | - Rita O'Rourke
- The Jackson Laboratory, Bar Harbor, ME, United States
| | | | - Cynthia Ingraham
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | - Melisa Belanger
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | - Zackary A Cope
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | - Gabriela J Little
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
| | | | - Carl Ash
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Adam Bleckert
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
| | - Tim Ragan
- The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States
| | | | | | | | - Paul R Territo
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States.,Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States
| | | | | | | | - Bruce T Lamb
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States.,Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States
| |
Collapse
|
32
|
Murai T, Sukoff Rizzo SJ. The Importance of Complementary Collaboration of Researchers, Veterinarians, and Husbandry Staff in the Successful Training of Marmoset Behavioral Assays. ILAR J 2021; 61:230-247. [PMID: 33501501 DOI: 10.1093/ilar/ilaa024] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 08/31/2020] [Accepted: 09/09/2020] [Indexed: 12/30/2022] Open
Abstract
Interest in marmosets as research models has seen exponential growth over the last decade, especially given that the research community is eager to improve on gaps with historical animal models for behavioral and cognitive disorders. The spectrum of human disease traits that present naturally in marmosets, as well as the range of analogous human behaviors that can be assessed in marmosets, makes them ideally suited as translational models for behavioral and cognitive disorders. Regardless of the specific research aims of any project, without close collaboration between researchers, veterinarians, and animal care staff, it would be impossible to meet these goals. Behavior is inherently variable, as are marmosets that are genetically and phenotypically diverse. Thus, to ensure rigor, reliability, and reproducibility in results, it is important that in the research environment, the animal's daily husbandry and veterinary needs are being met and align with the research goals while keeping the welfare of the animal the most critical and highest priority. Much of the information described herein provides details on key components for successful behavioral testing, based on a compendium of methods from peer-reviewed publications and our own experiences. Specific areas highlighted include habituation procedures, selection of appropriate rewards, optimization of testing environments, and ways to integrate regular veterinary and husbandry procedures into the research program with minimal disruptions to the behavioral testing plan. This article aims to provide a broad foundation for researchers new to establishing behavioral and cognitive testing paradigms in marmosets and especially for the veterinary and husbandry colleagues who are indispensable collaborators of these research projects.
Collapse
Affiliation(s)
- Takeshi Murai
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | |
Collapse
|
33
|
Vitek MP, Araujo JA, Fossel M, Greenberg BD, Howell GR, Rizzo SJS, Seyfried NT, Tenner AJ, Territo PR, Windisch M, Bain LJ, Ross A, Carrillo MC, Lamb BT, Edelmayer RM. Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank. Alzheimers Dement (N Y) 2021; 6:e12114. [PMID: 33457489 PMCID: PMC7798310 DOI: 10.1002/trc2.12114] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 07/04/2020] [Accepted: 07/09/2020] [Indexed: 12/12/2022]
Abstract
Over 5 million Americans and 50 million individuals worldwide are living with Alzheimer's disease (AD). The progressive dementia associated with AD currently has no cure. Although clinical trials in patients are ultimately required to find safe and effective drugs, animal models of AD permit the integration of brain pathologies with learning and memory deficits that are the first step in developing these new drugs. The purpose of the Alzheimer's Association Business Consortium Think Tank meeting was to address the unmet need to improve the discovery and successful development of Alzheimer's therapies. We hypothesize that positive responses to new therapies observed in validated models of AD will provide predictive evidence for positive responses to these same therapies in AD patients. To achieve this goal, we convened a meeting of experts to explore the current state of AD animal models, identify knowledge gaps, and recommend actions for development of next-generation models with better predictability. Among our findings, we all recognize that models reflecting only single aspects of AD pathogenesis do not mimic AD. Models or combinations of new models are needed that incorporate genetics with environmental interactions, timing of disease development, heterogeneous mechanisms and pathways, comorbidities, and other pathologies that lead to AD and related dementias. Selection of the best models requires us to address the following: (1) which animal species, strains, and genetic backgrounds are most appropriate; (2) which models permit efficient use throughout the drug development pipeline; (3) the translatability of behavioral-cognitive assays from animals to patients; and (4) how to match potential AD therapeutics with particular models. Best practice guidelines to improve reproducibility also need to be developed for consistent use of these models in different research settings. To enhance translational predictability, we discuss a multi-model evaluation strategy to de-risk the successful transition of pre-clinical drug assets to the clinic.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Nicholas T. Seyfried
- Departments of Biochemistry and NeurologyEmory School of MedicineAtlantaGeorgiaUSA
| | - Andrea J. Tenner
- Department of Molecular Biology and BiochemistryUniversity of CaliforniaIrvineCaliforniaUSA
| | | | | | - Lisa J. Bain
- Independent Science and Medical WriterElversonPennsylvaniaUSA
| | - April Ross
- Former Alzheimer's Association EmployeeChicagoIllinoisUSA
| | | | - Bruce T. Lamb
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | | |
Collapse
|
34
|
Uyar A, Pandey RS, Preuss C, Kotredes KP, Oblak AL, Logsdon BA, Rizzo SJS, Howell G, Lamb BT, Sasner M, Carter GW. N‐of‐1‐pathways transcriptomic analysis reveals distinct subtypes of Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.046575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Asli Uyar
- The Jackson Laboratory Bar Harbor ME USA
| | | | | | | | | | | | | | | | - Bruce T. Lamb
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | | | |
Collapse
|
35
|
Lamb BT, Palkowitz AD, Howell G, Carter GW, Territo PR, Oblak AL, Rizzo SJS, Sasner M. Identification and characterization of immune‐focused therapeutic targets in the MODEL‐AD and TREAT‐AD consortia. Alzheimers Dement 2020. [DOI: 10.1002/alz.044157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Bruce T. Lamb
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Palkowitz AD, Lamb BT, Oblak AL, Reeves CAL, Territo PR, Rizzo SJS. The IUSM‐Purdue Alzheimer’s Disease Drug Discovery Center: A member of the NIH‐funded TREAT‐AD consortium. Alzheimers Dement 2020. [DOI: 10.1002/alz.041107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | - Bruce T. Lamb
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | | | | | | | |
Collapse
|
37
|
Kotredes KP, Preuss C, Pandey RS, Territo PR, Oblak AL, Kaddurah‐Daouk RF, Arnold M, Seyfried NT, Duong D, Williams HM, Lamb BT, Rizzo SJS, Carter GW, Sasner M, Howell G. Hallmarks of late‐onset Alzheimer’s disease in a humanized mouse model. Alzheimers Dement 2020. [DOI: 10.1002/alz.045162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | | | | | | | | | - Matthias Arnold
- Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health Neuherberg Germany
| | | | - Duc Duong
- Emory University School of Medicine Atlanta GA USA
| | | | - Bruce T. Lamb
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | | | | | | | |
Collapse
|
38
|
Territo PR, Quinney SK, Biesdorf C, Masters AR, Onos K, Haynes L, Keezer K, Cope ZA, Meyer JA, Peters J, Persohn SC, Figueiredo L, Bedwell AA, Eldridge K, Speedy R, Sasner M, Howell G, Carter GW, Oblak AL, Lamb BT, Rizzo SJS. Pharmacokinetic, pharmacodynamic and transcriptomic analyses of verubecestat treatment in 5XFAD mice. Alzheimers Dement 2020. [DOI: 10.1002/alz.041491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - Carla Biesdorf
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | | | - Jill A. Meyer
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | - Lucas Figueiredo
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | | | | - Rachael Speedy
- Indiana University School of Medicine Indianapolis IN USA
| | | | | | | | | | - Bruce T. Lamb
- Indiana University Stark Neurosciences Research Institute Indianapolis IN USA
| | | |
Collapse
|
39
|
Kozak R, Kiss T, Dlugolenski K, Johnson DE, Gorczyca RR, Kuszpit K, Harvey BD, Stolyar P, Sukoff Rizzo SJ, Hoffmann WE, Volfson D, Hajós M, Davoren JE, Abbott AL, Williams GV, Castner SA, Gray DL. Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation. Front Pharmacol 2020; 11:1005. [PMID: 32733245 PMCID: PMC7358525 DOI: 10.3389/fphar.2020.01005] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/22/2020] [Indexed: 12/16/2022] Open
Abstract
Selective activation of dopamine D1 receptors remains a promising pro-cognitive therapeutic strategy awaiting robust clinical investigation. PF-6142 is a key example from a recently disclosed novel series of non-catechol agonists and partial agonists of the dopamine D1/5 receptors (D1R) that exhibit pharmacokinetic (PK) properties suitable for oral delivery. Given their reported potential for functionally biased signaling compared to known catechol-based selective agonists, and the promising rodent PK profile of PF-6142, we utilized relevant in vivo assays in male rodents and male and female non-human primates (NHP) to evaluate the pharmacology of this new series. Studies in rodents showed that PF-6142 increased locomotor activity and prefrontal cortex acetylcholine release, increased time spent in wakefulness, and desynchronized the EEG, like known D1R agonists. D1R selectivity of PF-6142 was supported by lack of effect in D1R knock-out mice and blocked response in the presence of the D1R antagonist SCH-23390. Further, PF-6142 improved performance in rodent models of NMDA receptor antagonist-induced cognitive dysfunction, such as MK-801-disrupted paired-pulse facilitation, and ketamine-disrupted working memory performance in the radial arm maze. Similarly, PF-6142 reversed ketamine-induced deficits in NHP performing the spatial delayed recognition task. Of importance, PF-6142 did not alter the efficacy of risperidone in assays predictive of antipsychotic-like effect in rodents including pre-pulse inhibition and conditioned avoidance responding. These data support the continued development of non-catechol based D1R agonists for the treatment of cognitive impairment associated with brain disorders including schizophrenia.
Collapse
Affiliation(s)
- Rouba Kozak
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Tamás Kiss
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Keith Dlugolenski
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - David E Johnson
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | | | - Kyle Kuszpit
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Brian D Harvey
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Polina Stolyar
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | | | | | - Dmitri Volfson
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Mihaly Hajós
- Global Research and Development, Pfizer Inc., Groton, CT, United States.,Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | | | - Amanda L Abbott
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - Graham V Williams
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - Stacy A Castner
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - David L Gray
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| |
Collapse
|
40
|
Sukoff Rizzo SJ, Masters A, Onos KD, Quinney S, Sasner M, Oblak A, Lamb BT, Territo PR. Improving preclinical to clinical translation in Alzheimer's disease research. Alzheimers Dement (N Y) 2020; 6:e12038. [PMID: 32548237 PMCID: PMC7293992 DOI: 10.1002/trc2.12038] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 05/11/2020] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Preclinical testing in animal models is a critical component of the drug discovery and development process. While hundreds of interventions have demonstrated preclinical efficacy for ameliorating cognitive impairments in animal models, none have confirmed efficacy in Alzheimer's disease (AD) clinical trials. Critically this lack of translation to the clinic points in part to issues with the animal models, the preclinical assays used, and lack of scientific rigor and reproducibility during execution. In an effort to improve this translation, the Preclinical Testing Core (PTC) of the Model Organism Development and Evaluation for Late-onset AD (MODEL-AD) consortium has established a rigorous screening strategy with go/no-go decision points that permits unbiased assessments of therapeutic agents. METHODS An initial screen evaluates drug stability, formulation, and pharmacokinetics (PK) to confirm appreciable brain exposure in the disease model at the pathologically relevant ages, followed by pharmacodynamics (PD) and predictive PK/PD modeling to inform the dose regimen for long-term studies. The secondary screen evaluates target engagement and disease modifying activity using non-invasive positron emission tomography/magnetic resonance imaging (PET/MRI). Provided the compound meets its "go" criteria for these endpoints, evaluation for efficacy on behavioral endpoints are conducted. RESULTS Validation of this pipeline using tool compounds revealed the importance of critical quality control (QC) steps that researchers need to be aware of when executing preclinical studies. These include confirmation of the active pharmaceutical ingredient and at the precise concentration expected; and an experimental design that is well powered and in line with the Animal Research Reporting of In vivo Experiments (ARRIVE) guidelines. DISCUSSION Taken together our experience executing a rigorous screening strategy with QC checkpoints provides insight to the challenges of conducting translational studies in animal models. The PTC pipeline is a National Institute on Aging (NIA)-supported resource accessible to the research community for investigators to nominate compounds for testing (https://stopadportal.synapse.org/), and these resources will ultimately enable better translational studies to be conducted.
Collapse
Affiliation(s)
| | - Andi Masters
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | | | - Sara Quinney
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | | | - Adrian Oblak
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | - Bruce T. Lamb
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | - Paul R Territo
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
| | - for the MODEL‐AD consortium
- University of Pittsburgh School of Medicine ‐ Aging InstitutePittsburghPennsylvaniaUSA
- Indiana University School of MedicineStark Neurosciences Research InstituteIndianapolisIndianaUSA
- The Jackson LaboratoryBar HarborMaineUSA
- Sage BionetworksSeattleWashingtonUSA
| |
Collapse
|
41
|
Sukoff Rizzo SJ, McTighe S, McKinzie DL. Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies. Handb Exp Pharmacol 2020; 257:147-162. [PMID: 31595415 DOI: 10.1007/164_2019_282] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Animal models consisting of inbred laboratory rodent strains have been a powerful tool for decades, helping to unravel the underpinnings of biological problems and employed to evaluate potential therapeutic treatments in drug discovery. While inbred strains demonstrate relatively reliable and predictable responses, using a single inbred strain alone or as a background to a mutation is analogous to running a clinical trial in a single individual and their identical twins. Indeed, complex etiologies drive the most common human diseases, and a single inbred strain that is a surrogate of a single genome, or data generated from a single sex, is not representative of the genetically diverse patient populations. Further, pharmacological and toxicology data generated in otherwise healthy animals may not translate to disease states where physiology, metabolism, and general health are compromised. The purpose of this chapter is to provide guidance for improving generalizability of preclinical studies by providing insight into necessary considerations for introducing systematic variation within the study design, such as genetic diversity, the use of both sexes, and selection of appropriate age and disease model. The outcome of implementing these considerations should be that reproducibility and generalizability of significant results are significantly enhanced leading to improved clinical translation.
Collapse
|
42
|
Sayed-Zahid AA, Sher RB, Sukoff Rizzo SJ, Anderson LC, Patenaude KE, Cox GA. Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy. Hum Mol Genet 2019; 28:2635-2647. [PMID: 31216357 PMCID: PMC6687948 DOI: 10.1093/hmg/ddz068] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Revised: 03/12/2019] [Accepted: 03/21/2019] [Indexed: 01/13/2023] Open
Abstract
Congenital muscular dystrophy with megaconial myopathy (MDCMC) is an autosomal recessive disorder characterized by progressive muscle weakness and wasting. The observation of megamitochondria in skeletal muscle biopsies is exclusive to this type of MD. The disease is caused by loss of function mutations in the choline kinase beta (CHKB) gene which results in dysfunction of the Kennedy pathway for the synthesis of phosphatidylcholine. We have previously reported a rostrocaudal MD (rmd) mouse with a deletion in the Chkb gene resulting in an MDCMC-like phenotype, and we used this mouse to test gene therapy strategies for the rescue and alleviation of the dystrophic phenotype. Introduction of a muscle-specific Chkb transgene completely rescues motor and behavioral function in the rmd mouse model, confirming the cell-autonomous nature of the disease. Intramuscular gene therapy post-disease onset using an adeno-associated viral 6 (AAV6) vector carrying a functional copy of Chkb is also capable of rescuing the dystrophy phenotype. In addition, we examined the ability of choline kinase alpha (Chka), a gene paralog of Chkb, to improve dystrophic phenotypes when upregulated in skeletal muscles of rmd mutant mice using a similar AAV6 vector. The sum of our results in a preclinical model of disease suggest that replacement of the Chkb gene or upregulation of endogenous Chka could serve as potential lines of therapy for MDCMC patients.
Collapse
Affiliation(s)
- Ambreen A Sayed-Zahid
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
- The Jackson Laboratory, Bar Harbor, ME, USA
| | | | - Stacey J Sukoff Rizzo
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
| | - Laura C Anderson
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
| | | | - Gregory A Cox
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, USA
| |
Collapse
|
43
|
Graham LC, Grabowska WA, Chun Y, Risacher SL, Philip VM, Saykin AJ, Sukoff Rizzo SJ, Howell GR. Exercise prevents obesity-induced cognitive decline and white matter damage in mice. Neurobiol Aging 2019; 80:154-172. [PMID: 31170535 PMCID: PMC7846054 DOI: 10.1016/j.neurobiolaging.2019.03.018] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 03/26/2019] [Accepted: 03/27/2019] [Indexed: 01/12/2023]
Abstract
Obesity in the western world has reached epidemic proportions, and yet the long-term effects on brain health are not well understood. To address this, we performed transcriptional profiling of brain regions from a mouse model of western diet (WD)-induced obesity. Both the cortex and hippocampus from C57BL/6J (B6) mice fed either a WD or a control diet from 2 months of age to 12 months of age (equivalent to midlife in a human population) were profiled. Gene set enrichment analyses predicted that genes involved in myelin generation, inflammation, and cerebrovascular health were differentially expressed in brains from WD-fed compared to control diet-fed mice. White matter damage and cerebrovascular decline were evident in brains from WD-fed mice using immunofluorescence and electron microscopy. At the cellular level, the WD caused an increase in the numbers of oligodendrocytes and myeloid cells suggesting that a WD is perturbing myelin turnover. Encouragingly, cerebrovascular damage and white matter damage were prevented by exercising WD-fed mice despite mice still gaining a significant amount of weight. Collectively, these data show that chronic consumption of a WD in B6 mice causes obesity, neuroinflammation, and cerebrovascular and white matter damage, but these potentially damaging effects can be prevented by modifiable risk factors such as exercise.
Collapse
Affiliation(s)
- Leah C Graham
- The Jackson Laboratory, Bar Harbor, ME, USA; Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA
| | - Weronika A Grabowska
- The Jackson Laboratory, Bar Harbor, ME, USA; College of the Atlantic, Bar Harbor, ME, USA
| | - Yoona Chun
- The Jackson Laboratory, Bar Harbor, ME, USA
| | - Shannon L Risacher
- Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Andrew J Saykin
- Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Gareth R Howell
- The Jackson Laboratory, Bar Harbor, ME, USA; Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
| |
Collapse
|
44
|
Uyar A, Oblak AL, Williams HM, Pandey RS, Kotredes KP, Preuss C, Logsdon BA, Sukoff Rizzo SJ, Howell G, Lamb BT, Sasner M, Carter GW. P4-098: TRANSCRIPTOMIC ALTERATIONS DRIVEN BY THE TREM2*R47H ALLELE VARY ACROSS DIFFERENT TRANSGENIC MOUSE MODELS. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.3758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Asli Uyar
- The Jackson Laboratory; Bar Harbor ME USA
| | | | | | | | | | | | | | | | | | - Bruce T. Lamb
- Indiana University, Stark Neurosciences Research Institute; Indianapolis IN USA
| | | | | |
Collapse
|
45
|
Oblak AL, Williams HM, Jadhav V, Tsai A, Soni D, Ingraham C, Kotredes KP, Uyar A, Pandey RS, Preuss C, Logsdon B, Territo PR, Sukoff Rizzo SJ, Sasner M, Carter GW, Howell G, Lamb BT. P4-091: THE TREM2*R47H VARIANT ALTERS EXPRESSION AND FUNCTION IN MOUSE MODELS OF ALZHEIMER'S DISEASE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.3751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Adrian L. Oblak
- Stark Neurosciences Research Institute; Indianapolis IN USA
- Indiana University School of Medicine; Indianapolis IN USA
| | | | - Vaishnavi Jadhav
- Stark Neurosciences Research Institute; Indianapolis IN USA
- Indiana University School of Medicine; Indianapolis IN USA
| | - Andy Tsai
- Stark Neurosciences Research Institute; Indianapolis IN USA
- Indiana University School of Medicine; Indianapolis IN USA
| | - Disha Soni
- Stark Neurosciences Research Institute; Indianapolis IN USA
- Indiana University School of Medicine; Indianapolis IN USA
| | - Cynthia Ingraham
- Indiana University, Stark Neurosciences Research Institute; Indianapolis IN USA
| | | | - Asli Uyar
- The Jackson Laboratory; Bar Harbor ME USA
| | | | | | | | | | | | | | | | | | - Bruce T. Lamb
- Indiana University, Stark Neurosciences Research Institute; Indianapolis IN USA
| | | |
Collapse
|
46
|
Onos KD, Uyar A, Keezer KJ, Jackson HM, Preuss C, Acklin CJ, O’Rourke R, Buchanan R, Cossette TL, Sukoff Rizzo SJ, Soto I, Carter GW, Howell GR. Enhancing face validity of mouse models of Alzheimer's disease with natural genetic variation. PLoS Genet 2019; 15:e1008155. [PMID: 31150388 PMCID: PMC6576791 DOI: 10.1371/journal.pgen.1008155] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 06/17/2019] [Accepted: 04/24/2019] [Indexed: 01/01/2023] Open
Abstract
Classical laboratory strains show limited genetic diversity and do not harness natural genetic variation. Mouse models relevant to Alzheimer's disease (AD) have largely been developed using these classical laboratory strains, such as C57BL/6J (B6), and this has likely contributed to the failure of translation of findings from mice to the clinic. Therefore, here we test the potential for natural genetic variation to enhance the translatability of AD mouse models. Two widely used AD-relevant transgenes, APPswe and PS1de9 (APP/PS1), were backcrossed from B6 to three wild-derived strains CAST/EiJ, WSB/EiJ, PWK/PhJ, representative of three Mus musculus subspecies. These new AD strains were characterized using metabolic, functional, neuropathological and transcriptional assays. Strain-, sex- and genotype-specific differences were observed in cognitive ability, neurodegeneration, plaque load, cerebrovascular health and cerebral amyloid angiopathy. Analyses of brain transcriptional data showed strain was the greatest driver of variation. We identified significant variation in myeloid cell numbers in wild type mice of different strains as well as significant differences in plaque-associated myeloid responses in APP/PS1 mice between the strains. Collectively, these data support the use of wild-derived strains to better model the complexity of human AD.
Collapse
Affiliation(s)
- Kristen D. Onos
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | - Asli Uyar
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | - Kelly J. Keezer
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | | | - Christoph Preuss
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | - Casey J. Acklin
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | - Rita O’Rourke
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | - Rebecca Buchanan
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
| | | | | | - Ileana Soto
- Department of Biomedical and Translational Sciences, Rowan University, Glassboro, New Jersey, United States of America
| | - Gregory W. Carter
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, Maine, United States of America
| | - Gareth R. Howell
- The Jackson Laboratory, Bar Harbor, Maine, United States of America
- Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America
- Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, Maine, United States of America
| |
Collapse
|
47
|
Harrison DE, Strong R, Alavez S, Astle CM, DiGiovanni J, Fernandez E, Flurkey K, Garratt M, Gelfond JAL, Javors MA, Levi M, Lithgow GJ, Macchiarini F, Nelson JF, Sukoff Rizzo SJ, Slaga TJ, Stearns T, Wilkinson JE, Miller RA. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell 2019; 18:e12898. [PMID: 30688027 PMCID: PMC6413665 DOI: 10.1111/acel.12898] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 10/01/2018] [Accepted: 10/29/2018] [Indexed: 12/31/2022] Open
Abstract
To follow-up on our previous report that acarbose (ACA), a drug that blocks postprandial glucose spikes, increases mouse lifespan, we studied ACA at three doses: 400, 1,000 (the original dose), and 2,500 ppm, using genetically heterogeneous mice at three sites. Each dose led to a significant change (by log-rank test) in both sexes, with larger effects in males, consistent with the original report. There were no significant differences among the three doses. The two higher doses produced 16% or 17% increases in median longevity of males, but only 4% or 5% increases in females. Age at the 90th percentile was increased significantly (8%-11%) in males at each dose, but was significantly increased (3%) in females only at 1,000 ppm. The sex effect on longevity is not explained simply by weight or fat mass, which were reduced by ACA more in females than in males. ACA at 1,000 ppm reduced lung tumors in males, diminished liver degeneration in both sexes and glomerulosclerosis in females, reduced blood glucose responses to refeeding in males, and improved rotarod performance in aging females, but not males. Three other interventions were also tested: ursolic acid, 2-(2-hydroxyphenyl) benzothiazole (HBX), and INT-767; none of these affected lifespan at the doses tested. The acarbose results confirm and extend our original report, prompt further attention to the effects of transient periods of high blood glucose on aging and the diseases of aging, including cancer, and should motivate studies of acarbose and other glucose-control drugs in humans.
Collapse
Affiliation(s)
| | - Randy Strong
- Barshop Institute for Longevity and Aging Studies; The University of Texas Health Science Center at San Antonio; San Antonio Texas
- Geriatric Research, Education and Clinical Center; South Texas Veterans Health Care System; San Antonio Texas
- Research Service; South Texas Veterans Health Care System; San Antonio Texas
- Department of Pharmacology; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | - Silvestre Alavez
- Buck Institute for Research on Aging; Novato California
- Metropolitan Autonomous University; Lerma Mexico
| | | | | | - Elizabeth Fernandez
- Barshop Institute for Longevity and Aging Studies; The University of Texas Health Science Center at San Antonio; San Antonio Texas
- Geriatric Research, Education and Clinical Center; South Texas Veterans Health Care System; San Antonio Texas
- Department of Pharmacology; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | | | - Michael Garratt
- Department of Pathology; University of Michigan; Ann Arbor Michigan
- Geriatrics Center; University of Michigan; Ann Arbor Michigan
| | - Jonathan A. L. Gelfond
- Department of Epidemiology & Biostatistics; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | - Martin A. Javors
- Department of Psychiatry; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | - Moshe Levi
- Georgetown University; Washington District of Columbia
| | | | | | - James F. Nelson
- Barshop Institute for Longevity and Aging Studies; The University of Texas Health Science Center at San Antonio; San Antonio Texas
- Department of Physiology; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | | | - Thomas J. Slaga
- Department of Pharmacology; The University of Texas Health Science Center at San Antonio; San Antonio Texas
| | | | - John Erby Wilkinson
- Unit for Laboratory Animal Medicine and Department of Pathology; University of Michigan; Ann Arbor Michigan
| | | |
Collapse
|
48
|
Peng Y, Shinde DN, Valencia CA, Mo JS, Rosenfeld J, Truitt Cho M, Chamberlin A, Li Z, Liu J, Gui B, Brockhage R, Basinger A, Alvarez-Leon B, Heydemann P, Magoulas PL, Lewis AM, Scaglia F, Gril S, Chong SC, Bower M, Monaghan KG, Willaert R, Plona MR, Dineen R, Milan F, Hoganson G, Powis Z, Helbig KL, Keller-Ramey J, Harris B, Anderson LC, Green T, Sukoff Rizzo SJ, Kaylor J, Chen J, Guan MX, Sellars E, Sparagana SP, Gibson JB, Reinholdt LG, Tang S, Huang T. Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. Hum Mol Genet 2018; 26:4937-4950. [PMID: 29040572 PMCID: PMC5886230 DOI: 10.1093/hmg/ddx377] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Accepted: 10/02/2017] [Indexed: 11/13/2022] Open
Abstract
Iron-sulfur (Fe-S) clusters are ubiquitous cofactors essential to various cellular processes, including mitochondrial respiration, DNA repair, and iron homeostasis. A steadily increasing number of disorders are being associated with disrupted biogenesis of Fe-S clusters. Here, we conducted whole-exome sequencing of patients with optic atrophy and other neurological signs of mitochondriopathy and identified 17 individuals from 13 unrelated families with recessive mutations in FDXR, encoding the mitochondrial membrane-associated flavoprotein ferrodoxin reductase required for electron transport from NADPH to cytochrome P450. In vitro enzymatic assays in patient fibroblast cells showed deficient ferredoxin NADP reductase activity and mitochondrial dysfunction evidenced by low oxygen consumption rates (OCRs), complex activities, ATP production and increased reactive oxygen species (ROS). Such defects were rescued by overexpression of wild-type FDXR. Moreover, we found that mice carrying a spontaneous mutation allelic to the most common mutation found in patients displayed progressive gait abnormalities and vision loss, in addition to biochemical defects consistent with the major clinical features of the disease. Taken together, these data provide the first demonstration that germline, hypomorphic mutations in FDXR cause a novel mitochondriopathy and optic atrophy in humans.
Collapse
Affiliation(s)
- Yanyan Peng
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | | | - C Alexander Valencia
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Jun-Song Mo
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Jill Rosenfeld
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | | | - Adam Chamberlin
- Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA
| | - Zhuo Li
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Jie Liu
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Baoheng Gui
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Rachel Brockhage
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Alice Basinger
- Department of Metabolic Genetics, Cook Children's Physician Network, Fort Worth, TX 76104, USA
| | - Brenda Alvarez-Leon
- Department of Metabolic Genetics, Cook Children's Physician Network, Fort Worth, TX 76104, USA
| | - Peter Heydemann
- Section of Pediatric Neurology, Rush University Medical Center, Chicago, IL 60612, USA
| | - Pilar L Magoulas
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Andrea M Lewis
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Fernando Scaglia
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Solange Gril
- Neuropediatric Department, Raul Carrea Institute for Neurological Research -FLENI, Montañeses 2325 (C1428AQK), Argentina
| | - Shuk Ching Chong
- Center of Inborn Errors of Metabolism, Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, China
| | - Matthew Bower
- Fairview Molecular Diagnostics Laboratory Neurology Clinic, University of Minnesota Medical Center, Minneapolis, MN 55454, USA
| | | | | | - Maria-Renee Plona
- Pediatric Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA
| | - Rich Dineen
- Pediatric Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA
| | | | - George Hoganson
- Pediatric Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA
| | - Zoe Powis
- Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA
| | | | | | | | | | | | | | - Julie Kaylor
- Arkansas Children's Hospital, Little Rock, AR 72202, USA
| | - Jiani Chen
- University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | - Min-Xin Guan
- Institute of Genetics, Zhejiang University, Hangzhou, China
| | | | - Steven P Sparagana
- Pediatric Neurology, Texas Scottish Rite Hospital for Children, Dallas, TX 75219, USA
| | | | | | - Sha Tang
- Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA
| | - Taosheng Huang
- Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| |
Collapse
|
49
|
Oblak AL, Williams HM, Baglietto-Vargas D, Mortazavi A, Wood MA, Green KN, Carter GW, Territo P, Sukoff Rizzo SJ, Sasner M, Macgregor GR, Tenner A, LaFerla F, Howell G, Lamb BT. P1‐130: MODEL‐AD: CHARACTERIZATION OF FAMILIAL AD MODELS (5XFAD, APP/PS1, HTAU, 3XTG‐AD). Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Adrian L. Oblak
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| | | | | | | | | | | | | | - Paul Territo
- Indiana University School of MedicineIndianapolisINUSA
| | | | | | | | | | | | | | - Bruce T. Lamb
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| |
Collapse
|
50
|
Williams HM, Oblak AL, O'Rourke R, Buchanan R, Keezer KJ, Ingraham C, Figueiredo L, Logsdon B, Sukoff Rizzo SJ, Carter GW, Howell G, Lamb BT, Sasner M. P4‐028: CHARACTERIZING THE APOE4/TREM2*R47H MOUSE MODEL FOR LATE ONSET ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
| | - Adrian L. Oblak
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| | | | | | | | - Cynthia Ingraham
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| | - Lucas Figueiredo
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| | | | | | | | | | - Bruce T. Lamb
- Indiana UniversityStark Neurosciences Research InstituteIndianapolisINUSA
| | | | | |
Collapse
|